Fall 2015

Inflammation and Cancer Research

Researchers at Fox Chase Cancer Center discuss their lab’s focus on the role inflammation plays in the initiation and progression of cancer. Q: Dr. Rall, can you start by talking about your research? Glenn F. Rall, PhD: Fox Chase has a long history of understanding how “normal” processes work so that we can more fully capture what goes wrong in particular diseases, such as cancer. My current work is focused on understanding the cellular and organ contexts that dictate whether the host response is protective or damaging, which is key to developing antiinflammatory strategies for both solid tumors and brain … Continue Reading »

American Association for Cancer Research

A New 3D Model System Developed to Mimic Mechanical Aspects of Pancreatic Cancer The scar-like fibrous tumor microenvironment known as desmoplasia is believed to be a major player in the progression of pancreatic cancer, yet its underlying biology and biomechanical influences remain poorly understood. Researchers recently presented a new multidisciplinary approach using a 3D human tissue mimetic model to study how human pancreatic fibrous extracellular matrices (ECMs) interact with pancreatic cancer cells displaying common pancreatic cancer mutations, such as lack of p53 and constitutively active KRAS. They combined cell-derived ECM and bioengineered materials with tunable stiffnesses mimicking the mechanical and … Continue Reading »

American Urological Association

Copy Number Alterations in Sarcomatoid RCC Examined Researchers at Fox Chase Cancer Center compared copy number alterations in sarcomatoid renal cell carcinoma (RCC) to those in clear cell, papillary, and chromophobe RCC to identify unique changes that might harbor genetic drivers of sarcomatoid RCC. The results were presented at the 2015 AUA Annual Meeting in New Orleans. Timothy Ito, MD, a surgical oncology fellow at Fox Chase, along with Joseph R. Testa, PhD, co-leader of Fox Chase’s Cancer Biology Program, and colleagues examined SNP microarrays performed on macrodissected tissue from 81 tumors; 17 had sarcomatoid differentiation. Copy number alterations present … Continue Reading »

Drugs that Reprogram Tumor Cells Introduce New Options for Blood Cancer Patients

ewc_TempleFC(2)0220150264-revA growing body of evidence supports the idea that epigenetic changes, which affect gene expression without altering the DNA sequence, play an important role in the initiation and progression of cancer. Because epigenetic therapies restore normal gene activity rather than kill cancer cells, they could be an attractive alternative for patients who cannot tolerate traditional chemotherapy. Continue Reading »

SPOTLIGHT on a Postdoctoral Associate: Q&A: Ilsiya Ibragimova, PhD

ilsiya2Ilsiya Ibragimova is a postdoctoral associate in the Cancer Epigenetics Program, which focuses on the role of epigenetic deregulation in cancer and determines how that information can improve patient outcomes. After completing her MS in biochemistry at Kazan State University in Russia, Ibragimova began her work on a PhD in molecular biology. Continue Reading »

Al-Saleem Presented with Lifetime Achievement Award

Fox Chase Cancer Center pathologist and Temple University Hospital alum Tahseen I. Al-Saleem, MD, has been recognized by the Iraqi Medical Sciences Association with its Lifetime Achievement Award for excellence in medical sciences. In Iraq, Al-Saleem was a professor of pathology and taught students and pathology fellows in the areas of medicine, pathology, and cancer research. He also served as president of the Iraqi Board of Pathology and consulted with the World Health Organization to establish a cancer registry there. Al-Saleem maintains a special emphasis on hematologic and urologic malignancies, has collaborated on the establishment of kidney and prostate cancer databases at Fox … Continue Reading »

Caris Designates Fox Chase a Caris Center of Excellence in Precision Medicine

Caris Life Sciences® has designated Fox Chase Cancer Center a center of excellence site in the Caris Centers of Excellence for Precision Medicine Network™. Wafik El-Deiry, MD, PhD, FACP, deputy cancer center director for translational research and co-program leader of Molecular Therapeutics, will join the Network Steering Committee to establish guidelines and research protocols for tumor profiling. Fox Chase will participate in the development of standards of care and best practices for integrating and utilizing molecular profiling in oncology practice while also striving to increase widespread adoption and patient access to precision medicine in clinical settings. Fox Chase will also … Continue Reading »

Anticancer Agent Offers Hope for Targeting Drug-Resistant Solid Tumors

Tony-OlszanskiPhase Ib clinical trial of three combination therapies for a broad range of solid tumors holds promise for overcoming resistance to currently available cancer drugs and expanding personalized treatment options. At the center of the trial is a compound called MLN2480, whose clinical development was made possible by a partnership between Fox Chase Cancer Center and Millennium Pharmaceuticals. Continue Reading »

Knowledge of Type II Kinase Inhibition May Help Improve Drug Design

THE TOPLINE Type II kinase inhibitors include a number of drugs showing promise in both the clinic and trials Developing additional Type II kinase inhibitors will likely improve the quality of the current anticancer drug cache Molecular factors that determine why important classes of cancer drugs are specific for their kinases are providing a rich data resource that can be used to create new, clinically useful kinase inhibitors—ultimately supporting precision treatment for patients. Research published in the Journal of Medicinal Chemistry represents an interdisciplinary collaboration between Roland L. Dunbrack, Jr., PhD, and Ronald Levy, PhD, from Fox Chase Cancer Center’s Molecular … Continue Reading »

Next Page »